U.S. FDA moves to smooth path for complex generic drugs

WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Monday announced a series of measures designed to speed to market complex generic drugs such as Mylan NV's emergency EpiPen in an effort to address the rising cost of pharmaceuticals.